Barcelona, July 4, 2019.- Grifols, a leading global producer of plasma-derived medicines, announced today that Xembify, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify is used to…Original Article
FDA Approves Xembify (immune globulin subcutaneous) for Primary Immunodeficiencies
